Ing D J, Glass R I, Woods P A, Simonetti M, Pallansch M A, Wilcox W D, Davidson B L, Sievert A J
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
Am J Dis Child. 1991 Aug;145(8):892-7. doi: 10.1001/archpedi.1991.02160080070023.
Between January and November 1989, we studied 174 infants aged 6 to 16 weeks in a randomized clinical trial to (1) determine the immunogenicity of a single dose of tetravalent rhesus rotavirus vaccine (RRV-TV) when administered with three different buffer regimens: no antacid buffer and small-volume (2.5-mL) and large-volume (30-mL) antacid buffer; and (2) examine the potential interference of RRV-TV on the immune response to oral polio vaccine. Immunogenicity of RRV-TV, measured as a fourfold rise in antibody titers to rotavirus, was similar in the groups receiving small- and large-dose buffer (45% and 49%, respectively) and significantly less in the group that received RRV-TV alone (23%). Administration of RRV-TV with oral polio vaccine did not significantly interfere with the neutralization response of oral polio vaccine poliovirus serotypes 1, 2, or 3, and overall, 29%, 87%, and 24% of the infants had a fourfold rise in titer to each serotype, respectively.
1989年1月至11月期间，我们在一项随机临床试验中研究了174名6至16周龄的婴儿，以：(1) 确定单剂量四价恒河猴轮状病毒疫苗（RRV-TV）与三种不同缓冲液方案联合使用时的免疫原性：无抗酸缓冲液以及小体积（2.5毫升）和大体积（30毫升）抗酸缓冲液；(2) 检查RRV-TV对口服脊髓灰质炎疫苗免疫反应的潜在干扰。以轮状病毒抗体滴度四倍升高衡量的RRV-TV免疫原性，在接受小剂量和大剂量缓冲液的组中相似（分别为45%和49%），而在单独接受RRV-TV的组中显著降低（23%）。RRV-TV与口服脊髓灰质炎疫苗联合使用并未显著干扰口服脊髓灰质炎疫苗1型、2型或3型脊髓灰质炎病毒血清型的中和反应，总体而言，分别有29%、87%和24%的婴儿对每种血清型的滴度有四倍升高。
